(Q33965415)

30 July 2017

Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study. (English)

1 reference

30 July 2017

3

Ludwig Kappos

1 reference

30 July 2017

5

Chris Polman

1 reference

30 July 2017

Paul O'Connor

1

1 reference

30 July 2017

Andrew Goodman

2

1 reference

30 July 2017

Fred Lublin

4

1 reference

30 July 2017

Richard A Rudick

6

1 reference

30 July 2017

Kathy Hauswirth

7

1 reference

30 July 2017

Lynda M Cristiano

8

1 reference

30 July 2017

Fiona Forrestal

9

1 reference

30 July 2017

Petra Duda

10

1 reference

30 July 2017

language of work or name

English

0 references

publication date

4 June 2014

1 reference

30 July 2017

1 reference

30 July 2017

83

1 reference

30 July 2017

1

1 reference

30 July 2017

78-86

1 reference

Natalizumab: bench to bedside and beyond

30 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4114173

Risk of natalizumab-associated progressive multifocal leukoencephalopathy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4114173

Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4114173

Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4114173

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4114173

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4114173

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4114173

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4114173

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4114173

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4114173

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4114173

Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4114173

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4114173

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4114173

Observations during an elective interruption of natalizumab treatment: a post-marketing study

29 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24898925

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24898925

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1212/WNL.0000000000000541

1 reference

30 July 2017

1 reference

30 July 2017

1 reference